Director, Strategy and Clinical Collaborations
Matthieu Rupin earned his M.Sc. in Health Engineering at Pharmacy University (IUP) in Montpellier, France. Prior to joining TRIO, he worked at Aventis from 1998 to 2001 on the docetaxel R&D team as a Clinical Research Associate in Johannesburg, South Africa and as a Study Manager in Paris, France. Mr. Rupin spent 11 years in Project Management, gaining experience in the supervision of global trials. He uses his expertise to analyze TRIO activity and improve TRIO’s operational performance.
Mr. Rupin also created the Clinical Start-up Unit, allowing for faster activation of investigational sites. He supports the development of partnerships with investigators to further TRIO’s scientific objectives.